DotLab announces three granted patents for its non-invasive test for endometriosis, DotEndo™
Via its clinical studies, DotLab has pioneered medical tests enabled by single-stranded, non-coding RNAs called microRNAs in circulating body fluids such as blood and saliva.
- Via its clinical studies, DotLab has pioneered medical tests enabled by single-stranded, non-coding RNAs called microRNAs in circulating body fluids such as blood and saliva.
- The inventions embodied in the portfolio of granted patents U.S. Patent No.
- 11,315,660 B2 also include the company's proprietary machine learning algorithms to detect, predict, diagnose, and monitor the presence or absence of the disease.
- EMPOWER is the most robust clinical study of its type ever performed, making it an excellent foundation for thecommercial test.